Health Care & Life Sciences » Pharmaceuticals | Hybio Pharmaceutical Co. Ltd.

Hybio Pharmaceutical Co. Ltd. | Balance Sheet

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
447
701
187
881
1,268
1,564
Total Accounts Receivable
176
239
666
815
1,177
1,279
Inventories
28
49
121
137
143
162
Other Current Assets
15
2
5
10
10
16
Total Current Assets
667
991
979
1,842
2,599
3,021
Net Property, Plant & Equipment
502
538
919
966
1,096
1,334
Total Investments and Advances
-
-
134
156
150
218
Intangible Assets
56
86
1,397
1,370
1,326
889
Other Assets
48
69
97
99
93
150
Total Assets
1,289
1,697
3,546
4,457
5,298
5,660
ST Debt & Current Portion LT Debt
-
-
100
-
466
Accounts Payable
5
4
26
53
49
Income Tax Payable
10
3
23
20
10
Other Current Liabilities
61
111
269
257
340
Total Current Liabilities
76
118
419
331
865
Long-Term Debt
-
199
401
421
459
Deferred Taxes
15
15
18
18
29
Total Liabilities
76
317
821
758
1,329
Common Equity (Total)
1,124
1,296
2,637
3,605
3,885
Total Shareholders' Equity
1,124
1,296
2,637
3,605
3,885
Total Equity
1,124
1,296
2,637
3,605
3,885
Liabilities & Shareholders' Equity
1,289
1,697
3,546
4,457
5,298
Non-Equity Reserves
88
84
88
94
84

About Hybio Pharmaceutical Co.

View Profile
Address
4/F, Hybio Biomedical Park Office
Shenzhen Guangdong 518057
China
Employees -
Website http://www.hybio.com.cn
Updated 07/08/2019
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of polypeptide drugs. It offers Desmopressin acetate injection, Thymopentin, Somatostatin, Terlipressin, and Carbetocin for Injection. It focuses on building a digitalized chronic diseases management platform with the combination of drugs, medical instruments, and Internet.